NEUROLIXIS - Key Persons
Job Titles:
- CEO
- Co - Founder
- Member of the Management Team
- President
Dr. Newman-Tancredi has over 25 years' experience of neuroscience research and drug discovery. Prior to co-founding Neurolixis, he was Director of Neurobiology and Project Manager at Pierre Fabre Laboratories where he led multi-disciplinary programs that identified and characterized novel antipsychotics, antidepressants and analgesics. Prior to Pierre Fabre, Dr. Newman-Tancredi led a molecular pharmacology group at the Servier Research Institute where he was responsible for screening of NCEs and investigating signal transduction mechanisms of monoamine receptors. Drugs characterized in the course of Dr. Newman-Tancredi's work include milnacipran (Savella ®), piribedil (Trivastal ®), agomelatine (Valdoxan ®), levomilnacipran (Fetzima ®) and befiradol (NLX-112). In addition, Dr. Newman-Tancredi managed the program that led to the discovery of the serotonergic "biased agonist", F15599 (NLX-101).
Dr. Newman-Tancredi has extensive experience of team management, integrating medicinal chemistry, pharmacology, early ADMET and preclinical development, and collaborating with academic researchers. He has published over 200 articles in peer-reviewed journals, co-authored patents on NCEs and given presentations to a wide variety of audiences. He serves on the Editorial Board of the International Journal of Neuropsychopharmacology, as European Councillor of the International Society for Serotonin Research and as an independent drug discovery consultant. Dr. Newman-Tancredi received his BSc with honours in Biochemistry, followed by a PhD and a DSc in neuropharmacology from the University of Kent at Canterbury, U.K.
Dr. Newman-Tancredi has broad expertise in neuroscience drug discovery and early pre-clinical development. He was previously Director of Neurobiology and Project Manager at Pierre Fabre Laboratories. More...
Dr. Jankosky, USA, is board certified in both neurology and occupational and environmental medicine. He has high level experience in FDA and as a Navy Captain where he held executive positions. He maintains adjunct faculty appointments at the University of Maryland and the Uniformed Services University. More...
Dr Abdala Sheik is an expert on the neural circuits involved in generating respiratory rhythm, sympathetic activity and blood pressure. In particular, her work has advanced understanding of 5-HT1A receptors in Rett syndrome.
Job Titles:
- Member of the Advisory Board
- Chairman of the Board of Epirus Biopharmaceuticals, Inc
Dr. Corrigan (Boston, USA) has profound understanding of drug develoment and clinical trials strategy in the pharmaceutical and biotechnology environment. He has extensive management experience in several large pharmaceutical companies More...
Dr. Corrigan is Chairman of the Board of Epirus Biopharmaceuticals, Inc. a public biopharmaceutical company, and from 2010 to 2014, he previously served as a director, president and chief executive officer of Zalicus Inc. prior to its merger with Epirus Biopharmaceuticals in July 2014. Prior to Zalicus, Dr. Corrigan joined the specialty pharmaceutical company Sepracor Inc. in 2003 (now known as Sunovion Pharmaceuticals, Inc.) where he served as Executive Vice President of Research and Development until December 2009. Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, where he served most recently as Group Vice President of Global Clinical Research and Experimental Medicine.
Before entering pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina, School of Medicine, focusing on psychoneuroendocrinology; he maintains a faculty appointment as Adjunct Professor in the Psychiatry Dept. He is a Distinguished Fellow of the American Psychiatric Association. Dr. Corrigan has also chaired the Scientific Committee of the boards of directors of Avanir Pharmaceuticals and of Cubist Pharmaceuticals, Inc. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.
Job Titles:
- Director, Clinical Development
Dr Herbrecht has over 25 years of experience in the Human and Veterinary Pharmaceutical Industry, working in three main areas: clinical development, quality assurance and regulatory affairs. More...
Dr Herbrecht has over 25 years of experience in the Human and Veterinary Pharmaceutical Industry, working in three main areas: clinical development, quality assurance and regulatory affairs. Dr Herbrecht started her career in 1993 as a CRA in a CRO (FDM Pharma) where she monitored clinical trials, and then as logistical coordinator for the outsourced CRAs. In 1995 she joined the Clinical Development Department of Theramex as a CRA (clinical project managers support, investigators follow-up, contact person for clinical trial management). From 2001, she worked as a QA Officer at Manufacturing perimeter at Teva Pharmaceuticals (maintenance of quality documentation, support to QC and manufacturing teams, audits, non-conformities follow up). Then, from 2006, she took the position of Regulatory Affairs Manager (MA maintenance and geoextension, regulatory strategy, management of answers to health authorities). From 2015, she joined Virbac and acted as Life Cycle Manager of veterinary biological products (pet vaccines) (CMC writing , technical support for affiliates, compliance activities). Over the past 14 years, she has developed an expertise in EU as well as international pharmaceutical regulations in therapeutic areas such as gynaecology, dermatology and, more recently, pet vaccines, by contributing to the writing and maintenance of analytical and production part of Marketing Authorization dossiers.
Job Titles:
- Member of the Management Team
- Senior VP, Scientific Operations, COO
Dr. Kleven has spent over 25 years in the pharmaceutical industry with accomplishments in project management, compiling, reviewing, and submitting FDA compliant regulatory documents and NIH/DOD grants. Led teams of Ph.D./M.S. scientists, graduate students, and technicians in small to mid cap organizations. Author/Co-author on ca. 160 publications and presentations at national and international scientific meetings. Prior to Neurolixis, Dr. Kleven was previously Vice President, Product Development at Biousian Biosystems, Inc., Vice President, Scientific Operations at Ceptaris Therapeutics, Inc. and Head of Behavioral Pharmacology at the Centre de Recherche Pierre Fabre, CASTRES, France. Dr. Kleven received B.A. and B.S. degrees with honors in psychology, biology, and mathematics from Bemidji State University. He received a Ph.D. in Pharmacology from the University of Minnesota before completing his postdoctoral training in Psychiatry at The University of Chicago.
Dr. Kleven's research interest has been focused on drug discovery programs for Substance Use Disorders, schizophrenia, depression, anxiety, chronic pain, and neurological disorders. He has been successful in developing drug candidates in several of these disease areas, and has published extensively in peer-reviewed journals.
Dr. Kleven has wide experience in small and mid-sized pharma companies as a pharmacologist and manager of FDA, NIH and DOD-compliant dossiers. He was previously VP at Biousian Systems and Ceptaris. More...
Prof. Cenci Nilsson is a renowned neurobiologist and neurologist in the field of Parkinson's disease. Since 2005, she leads the Basal Ganglia Pathophysiology team at Lund University, and she is an advisor on funding institutions and international research organizations. She also serves on the Editorial Boards of several scientific journals.
Prof. Anna Wesołowska is an expert behavioral pharmacologist, particularly in the area of serotonergic receptors. She has a wide experience in investigating the role of 5-HT receptor subtypes as well as in identification of novel serotonergic ligands.
Job Titles:
- Member of the Advisory Board
- Member of the Management Team
Prof. Hoyer (Melbourne, Australia) has combined highly-cited fundamental research in receptor pharmacology with industrial drug discovery in pharmaceutical companies. He has detailed knowlege of the challenges facing target validation and drug development More...
Job Titles:
- Member of the Advisory Board
- Member of the Management Team
Prof. Artigas (Barcelona, Spain) is recognized as one of the foremost pioneers in the investigation of the mechanism of action of antidepressant and antipsychotic drugs, with particular interest in the role of neurotransmitters in brain areas controlling mood and cognition. More...
Job Titles:
- Member of the Management Team
- Pharmacologist
- Director, Pharmacology
Dr. Depoortere has twenty five years of expertise in pharmaceutical research as a team leader and pre-clinical neuropharmacologist, with a deep knowledge of multiple pre-clinical experimental and pharmacological paradigms and in-depth insight into the discovery and characterization of exploratory molecules and development candidates. He has actively participated to the identification and pharmacological profiling of novel antipsychotics, antidepressants and analgesics at Synthelabo (now part of the Sanofi conglomerate) and at Pierre Fabre Laboratories, before joining Neurolixis, a neuroscience-based venture, with the position of Director of Pharmacology. He has extensively interacted with preclinical research teams: medicinal chemists, in vitro pharmacologists, neurochemists, electrophysiologists, toxicologists and ADME researchers. He has also participated in project teams with clinicians, regulatory affairs specialists and resource planning managers, and has gained knowledge in novel target identification and validation. He has experience in team management (total of 7 PhDs and 15-20 technicians during the entire period). Finally, Dr. Depoortere has wide experience in the field of scientific writing, having published about 60 articles (or book chapters) in international peer-reviewed journals, over 100 posters for congress presentation and oral presentations, as well as numerous research reports. He has also acted as a referee for about 10 international scientific journals and reviewed around 80 manuscripts.
Dr. Depoortere is a highly experienced pharmacologist and participated in the characterization of antipsychotics and antidepressants. He was previously Senior Scientist at Sanofi and Synthelabo. More...
Job Titles:
- Member of the Management Team
- Vice - President, Drug Development
Dr. Johnson has more than 20 years experience in pharmaceutical research, preclinical and clinical drug development. Prior to joining Neurolixis, Dr. Johnson held a series of positions managing drug discovery, preclinical and clinical research at Cortex Pharmaceuticals, Inc (Irvine, CA), most recent of which was VP of Preclinical Development and Executive Officer. Prior to Cortex he was an Assistant Professor of Neurogerontology at the University of Southern California (USC; Los Angeles, CA), where he focused on the molecular biology and molecular pathology of Alzheimer's disease. Prior to joining the research faculty at USC, Dr. Johnson received post-doctoral training at the California Institute of Technology (CalTech; Pasadena, CA) and at USC. Dr. Johnson has served on a number of state (California) and federal (National Institute of Health) funding review panels, has been a reviewer for several aging and neurobiology journals, has published more than 50 articles and book chapters, and holds 1 patent. Dr. Johnson received a B.S. from Oregon State University and a Ph.D. in Biology from Purdue University (W. Lafayette, IN).
Dr. Johnson has extensive experience of pre-clinical and clinical drug development in neurobiology and neuropsychiatry. He was previously Vice-President and Executive Officer at Cortex Pharmaceuticals. More...
Prof. Leonardo leads a research team focusing on how temporal factors and genetic risk impact the expression of mental illness. He is an expert on the role of serotonin 5-HT1A receptor in regulating vulnerability to stress and depressive states.
Job Titles:
- Doctor of Pharmacy
- Researcher in Radioimaging
Violette Richin is Doctor of Pharmacy and graduated from the University of Lyon. She completed her training with a Master degree in Medicinal Chemistry and Molecular Pharmacology at the University of Paris. More...